CBR 비강내 전달
14 2월 2024
헤모제닉스 파마슈티컬스 PLC
("헤모제닉스 파마슈티컬스" 또는 "회사")
CBR 비강내 전달
Chimeric Bait Receptors for Combatting Airborne Viral Infections Can Be Delivered Intranasally
Hemogenyx Pharmaceuticals plc(LSE: HEMO), the clinical stage biopharmaceutical group, announces that it has demonstrated 생체내에서 that its proprietary Chimeric Bait Receptor ("CBR") can be delivered intranasally in the form of messenger RNA ("mRNA") for the potential treatment of airborne viral infections.
CBR-based countermeasures against viral infections that are include a novel method of their delivery. To satisfy real-world requirements for the deployment of such countermeasures, they must be both easy to administer and have a long shelf life at ambient temperatures. CBR is a platform technology under development that aims to program the immune cells that are responsible for innate immunity (e.g., macrophages) to eliminate viruses and certain malignant cells.
Our team of scientists has demonstrated 생체내에서 that mRNA encoding a CBR-based therapeutic can be mixed with a polymer and a solvent at room temperature to form polymer nanoparticles encapsulating mRNA. Such nanoparticles can be used to deliver CBR-coding mRNA into the upper respiratory tract ("URT") and lungs of small animals. Once administered, nanoparticles were shown to successfully deliver mRNA into the immune cells of the URT and lungs. The immune cells in turn begin making CBR molecules within hours post-application, potentially becoming active "defenders" against airborne infections.
As previously reported, the Company has been able to dramatically accelerate its research and development efforts by using Artificial Intelligence ("AI") and in-house synthesis of mRNA. AI tools allow the Company's scientists to triage variants of CBR constructs efficiently to select those with the greatest likelihood of success, while in-house mRNA synthesis facilitates the rapid building of CBR constructs.
Hemogenyx Pharmaceuticals의 CEO이자 공동 창업자인 Vladislav Sandler 박사는 다음과 같이 말했습니다. "This major breakthrough in the method of delivery of our CBR demonstrates that it could potentially be used as an off-the-shelf prevention and/or treatment for viral infections. Intranasal delivery of CBR would be both cost-efficient and easy to administer, making it ideal for the protection of both the civilian population and in biodefense."
시장 남용 규정(MAR) 공개
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement.
문의 :
헤모제닉스 파마슈티컬스 PLC | https://hemogenyx.com |
Vladislav Sandler 박사, CEO 겸 공동 창립자 | |
피터 레드몬드 (감독) | |
SP Angel 기업 금융 LLP | 전화 : + 44 (0) 20 3470 0470 |
매튜 존슨, 바딤 알렉산드르, 아담 카울 | |
피터하우스 캐피탈 리미티드 | 전화 : + 44 (0) 20 7469 0930 |
루시 윌리엄스, 던컨 베이시, 찰스 굿펠로우 |
헤모제닉스 파마슈티컬스(Hemogenyx Pharmaceuticals plc) 소개
Hemogenyx Pharmaceuticals는 상장 회사(LSE: HEMO)로 런던에 본사를 두고 있으며, 미국 운영 자회사인 Hemogenyx Pharmaceuticals LLC와 Immugenyx LLC는 뉴욕 시의 최첨단 연구 시설에 위치하고 있습니다.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.